Makes generic medicines in India and sells them in the US and Europe when brand-name patents expire.
At a glance
- Depends onUpstream position: supplies 5 industries, depends on 0
- ScaleMarket cap is above the global median
Makes generic medicines in India and sells them in the US and Europe when brand-name patents expire.
What this company is and how it runs — written from structure, not news.
Lupin files applications with the FDA to sell generic versions of branded drugs in the US, and every one of those applications names a specific building — either its Aurangabad or Tarapur facility in India — as the site where that drug is made. Because the approval is tied to the physical address rather than the company in the abstract, Lupin can ship product the moment a patent expires and no competitor's paperwork can fill that slot, but the same logic means that if the FDA issues a warning letter against either site, every drug registered to that address is frozen simultaneously — CVS and Walgreens cannot legally substitute from another supplier, so the shelf space goes empty regardless of how much inventory Lupin actually has. The risk is compounded by the fact that both the raw chemical ingredients and the finished pills are produced at those same two Indian sites, so a single enforcement action cuts off upstream supply and finished-product shipment at the same time. A competitor with API production in one country and tablet manufacturing in another would not face that kind of single-point failure, but building that kind of split footprint would also mean starting from scratch on FDA inspection history at each new site — a process measured in years, not months.
How does this company make money?
The company earns money by selling generic pills and capsules by the unit to wholesalers and distributors. When it is the first or only approved generic for a given drug, it can charge higher prices and keep margins wide. As more generic manufacturers receive their own approvals for the same molecule, competition pushes prices down, so the company's best earnings on any drug come in the early period after the brand-name patent expires.
What makes this company hard to replace?
Pharmacy chains like CVS and Walgreens cannot quickly swap in a different supplier because each replacement would need its own FDA bioequivalence approval, a process that takes multiple years. State-by-state generic substitution laws mean pharmacies can only dispense from the specific ANDA holder approved for that state, not just any generic version. Large hospital systems and pharmacy benefit managers also run their own multi-year vendor qualification processes before they will purchase from a new supplier.
What limits this company?
The FDA must physically inspect and formally clear Aurangabad or Tarapur before shipments can resume after any compliance problem. That process has historically taken months and cannot be sped up by spending more money. Because both the raw chemical ingredients and the finished pills are made at the same Indian sites, one compliance hold shuts down the whole supply chain — raw materials and finished products stop moving at the same time.
What does this company depend on?
The company cannot operate without FDA ANDA approvals for each generic drug it sells, facility inspection clearances from the US FDA for Aurangabad and Tarapur, Active pharmaceutical ingredient sourcing from Indian chemical manufacturers, Current Good Manufacturing Practice compliance at both Indian sites, and European Medicines Agency marketing authorizations for its European business.
Who depends on this company?
US pharmacy chains like CVS and Walgreens rely on the company to fill low-cost generic slots in their diabetes and cardiovascular drug lists — if supply stopped, those formulary spots would go unfilled. Indian domestic hospitals depend on its affordable branded formulations for everyday patient care. European generic distributors rely on a steady, low-cost API supply to maintain their own margins.
How does this company scale?
Adding production lines and buying bulk chemical ingredients in India is relatively cheap and straightforward, so manufacturing volume can grow without enormous new investment. What cannot scale quickly is the FDA relationship itself — any new facility the company might add would need its own multi-year inspection history and separate validation cycles before it could be named on a single US approval.
What external forces can significantly affect this company?
Changes in US-India trade policy could affect pharmaceutical import rules or add new tariffs, raising costs directly. The Indian rupee's value against the US dollar swings export margins up or down without the company doing anything differently. In Europe, post-Brexit regulatory changes have created additional filing requirements that did not previously exist for accessing UK and EU markets.
Where is this company structurally vulnerable?
If the FDA issued warning letters against both Aurangabad and Tarapur at the same time, every approval registered to those sites would be frozen at once. The company has no other named facilities to fall back on, so its entire US portfolio — cardiovascular, CNS, and diabetes drugs — would lose market access simultaneously.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations describe the present configuration: a high share of the trailing year's weekly closes were higher than the prior week, the company has reported positive net income in each of the last three annual periods, and the industry-benchmarked TTM operating cash flow margin is in the upper peer range.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
9 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Three observations have aligned: most-recent-quarter total cash is in the upper portion of its mapped range against most-recent-quarter total debt, EBITDA-to-total-liabilities is in the upper portion of its mapped range, and FCF-to-total-liabilities is in the upper portion of its mapped range.
How does this company use capital?
Net income is high relative to shareholders' equity; the absolute value of (pretax income − operating income) is large relative to sales; EBIT margin is above the company's historical median while recent sales growth is below baseline (industry-benchmarked).
Three observations co-occur: the weighted composite of net cash relative to market cap, OCF/revenue, operating margin, and ROE is in its elevated range; revenue increased every year for three years; net income was positive every year for three years. The configuration describes a present-state combination of capital structure, cash generation, profitability, and top-line growth.
Three margin observations have aligned: industry-benchmarked gross profit margin is in the upper peer range, operating income margin is in the upper portion of its mapped range, and industry-benchmarked TTM operating cash flow margin is in the upper peer range.
Three margin observations have aligned: industry-benchmarked gross profit margin is in the upper peer range, operating income margin is in the upper portion of its mapped range, and industry-benchmarked net profit margin is in the upper peer range.
Four observations co-occur: free cash flow positive each of the last three fiscal years, revenue increased each of the last three fiscal years, trailing-statistics OCF margin elevated, and book value increased each of the last four fiscal years. The configuration describes multi-year fundamental persistence across cash flow, top line, margin, and equity accumulation.
Three observations align: revenue has increased every year over the trailing three years, receivables have increased every year over the trailing four years, and operating cash flow margin is on the industry-benchmarked scale. The picture is concurrent growth in revenue and receivables with peer-relative cash-conversion context.
Three industry-benchmarked return-on-capital ratios are simultaneously in their elevated ranges: ROE, ROA, and operating ROA. Because ROA and operating ROA both fire alongside ROE, the configuration is not solely a function of equity multiplier; the underlying asset base is also producing elevated returns relative to peers.
Is this company growing?
Three observations align on a healthy multi-year growth profile: revenue grew every year over the trailing five-year window, operating margin in the most recent year is at an elevated level, and revenue grew every year over the trailing three-year window. Together they describe sustained top-line continuity at a high current margin level.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph